Blood‐based biomarkers for Alzheimer's disease

Abstract

Blood‐based biomarkers for identifying Alzheimer's disease (AD) pathology have been of considerable interest over the past decade and can offer a significant advantage over the currently available and validated cerebrospinal fluid and positron emission tomography biomarkers in terms of cost, invasiveness and accessibility. This review explores the role of three blood‐based biomarkers; plasma amyloid β, tau and neurofilament light chain, and their combination, in the identification of AD pathology and how they may be utilised in clinical practice.

Lecanemab for Alzheimer's disease: new hope or another false dawn?

“…In addition, amyloid PET scans and CSF testing are expensive and limited, and lumbar puncture is invasive. It is hoped that some of these difficulties may be overcome with the development of blood‐based biomarkers but this remains to be seen 17 . Furthermore, participants in the CLARITY AD trial had regular interval safety MRI brain scans to check for ARIA so this would require significant investment and restructuring to provide this resource in the NHS.…”